Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0720

+2.9%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	12/5/2014 1:18:52 PM
	of 13111

Provectus News Oncologists examine efficacy of rose bengal against cancer Friday December 5, 2014 A News Medical article discusses PV-10 clinical studies, as well as recent murine melanoma studies combining PV-10 and co-inhibitory blockade, and the recent surge in attention being given to combination therapies by both big pharma and the media. The article is available at www.news-medical.net/news/20141204/Oncologists-examine-efficacy-of-rose-bengal-against-cancer.aspx on the News Medical website. Study Finds Combined PV-10 And Immune Checkpoint Inhibitors Efficient In Melanoma Treatment Friday December 5, 2014 An article appearing on Melanoma News Today reports that during the 29th annual meeting of the Society for Immunotherapy of Cancer, Dr. Shari Pilon-Thomas of the Moffitt Cancer Center, presented a study titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma" revealing new results that encourage the combination of PV-10 and co-inhibitory blockade drugs for the treatment of melanoma. The article is available at melanomanewstoday.com on the Melanoma News Today website.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next